Bioprocess Automation Market Size, Share & Trends Analysis Report By Product & Services (Automation Consumables & Accessories, Process Automation Hardware), By Process Stage (Upstream, Downstream), By End Use, By Region, And Segment Forecasts, 2025 - 2033
Description
Bioprocess Automation Market Summary
The global bioprocess automation market size was estimated at USD 7.76 billion in 2024 and is projected to reach USD 22.41 billion by 2033, growing at a CAGR of 12.67% from 2025 to 2033, driven by rising demand for biologics, advancements in AI and robotics, and the need for regulatory compliance and efficiency.
Rising Demand for Biologics
The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a sharp increase in the development and use of monoclonal antibodies, vaccines, gene therapies, and other biologic products due to their effectiveness in treating complex diseases, including cancer, autoimmune disorders, and rare genetic conditions. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.
The need for bioprocess automation is anticipated to increase as the world's healthcare system depends more on biology for novel treatments, making it an essential part of contemporary pharmaceutical production. Automation in bioprocessing allows manufacturers to optimize production workflows, improve consistency, and increase throughput without compromising quality. Biopharmaceutical companies can produce larger biologics with reduced variability, faster turnaround times, and lower operational costs by integrating robotics, AI, and advanced monitoring systems.
Need for Efficiency and Cost Reduction
The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. Batch failures, inconsistent products, and higher production costs can result from labor-intensive, human error-prone manual or semi-automated processes. By implementing automated systems, businesses can increase productivity, decrease reliance on manual labor, and minimize errors, guaranteeing more consistent and dependable results across production batches.
Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.
Global Bioprocess Automation Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess automation market report based on product & service, process stage, end use, and region:
The global bioprocess automation market size was estimated at USD 7.76 billion in 2024 and is projected to reach USD 22.41 billion by 2033, growing at a CAGR of 12.67% from 2025 to 2033, driven by rising demand for biologics, advancements in AI and robotics, and the need for regulatory compliance and efficiency.
Rising Demand for Biologics
The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a sharp increase in the development and use of monoclonal antibodies, vaccines, gene therapies, and other biologic products due to their effectiveness in treating complex diseases, including cancer, autoimmune disorders, and rare genetic conditions. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.
The need for bioprocess automation is anticipated to increase as the world's healthcare system depends more on biology for novel treatments, making it an essential part of contemporary pharmaceutical production. Automation in bioprocessing allows manufacturers to optimize production workflows, improve consistency, and increase throughput without compromising quality. Biopharmaceutical companies can produce larger biologics with reduced variability, faster turnaround times, and lower operational costs by integrating robotics, AI, and advanced monitoring systems.
Need for Efficiency and Cost Reduction
The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. Batch failures, inconsistent products, and higher production costs can result from labor-intensive, human error-prone manual or semi-automated processes. By implementing automated systems, businesses can increase productivity, decrease reliance on manual labor, and minimize errors, guaranteeing more consistent and dependable results across production batches.
Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.
Global Bioprocess Automation Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global bioprocess automation market report based on product & service, process stage, end use, and region:
- Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
- Automation Consumables & Accessories
- Process Automation Hardware
- Software & Control Systems
- Integrated & Turnkey Solutions
- Services & Support
- Process Stage Outlook (Revenue, USD Million, 2021 - 2033)
- Upstream
- Downstream
- Process Development & Scale-up
- Fill/Finish & Packaging automation
- Quality Control & PAT
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical & biotech manufacturers
- CDMOs & CMOs
- Academic & research institutions
- Contract testing & analytical labs
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product & Services
- 1.2.2. Process Stage
- 1.2.3. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Details
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Impact Analysis
- 3.3.1.1. Rising demand for biologics
- 3.3.1.2. Need for efficiency and cost reduction
- 3.3.2. Market Restraint Impact Analysis
- 3.3.2.1. High Initial Investment Costs
- 3.3.2.2. Regulatory and Compliance Challenges
- 3.4. Business Environment Analysis
- 3.4.1. PESTLE Analysis
- 3.4.2. PORTER’S Five Forces Analysis
- Chapter 4. Product & Services Business Analysis
- 4.1. Product & Services Segment Dashboard
- 4.2. Global Bioprocess Automation Market Product & Services, Movement Analysis
- 4.3. Global Bioprocess Automation Market Size & Trend Analysis, by Product & Services, 2021 to 2033 (USD Million)
- 4.4. Automation Consumables & Accessories
- 4.4.1. Global automation consumables & accessories market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5. Process Automation Hardware
- 4.5.1. Global Process Automation Hardware market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.6. Software & Control Systems
- 4.6.1. Global software & control systems market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7. Integrated & Turnkey Solutions
- 4.7.1. Global integrated & turnkey solutions market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.8. Services & Support
- 4.8.1. Global services & support market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Process Stage Business Analysis
- 5.1. Process Stage Segment Dashboard
- 5.2. Global Bioprocess Automation Market Process Stage, Movement Analysis
- 5.3. Global Bioprocess Automation Market Size & Trend Analysis, by Process Stage, 2021 to 2033 (USD Million)
- 5.4. Upstream
- 5.4.1. Global upstream market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.5. Downstream
- 5.5.1. Global downstream market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.6. Process Development & Scale-up
- 5.6.1. Global process development & scale-up market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.7. Fill/Finish & Packaging automation
- 5.7.1. Global fill/finish & packaging automation market estimates and forecasts, 2021 - 2033 (USD Million)
- 5.8. Quality Control & PAT
- 5.8.1. Global quality control & PAT market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 6. End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Global Bioprocess Automation Market End Use, Movement Analysis
- 6.3. Global Bioprocess Automation Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Pharmaceutical & biotech manufacturers
- 6.4.1. Global Pharmaceutical & biotech manufacturers market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.5. CDMOs & CMOs
- 6.5.1. Global CDMOs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.6. Academic & research institutions
- 6.6.1. Global academic & research institutions market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.7. Contract testing & analytical labs
- 6.7.1. Global contract testing & analytical labs market estimates and forecasts, 2021 - 2033 (USD Million)
- 6.8. Others
- 6.8.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Bioprocess Automation Market: Regional Estimates and Trend Analysis, by Product, Product & Services, End Use, & End-Use
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 7.3. North America
- 7.3.1. North America bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Target Disease Prevalence
- 7.3.2.3. Competitive Scenario
- 7.3.2.4. Regulatory Framework
- 7.3.2.5. U.S. bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Target Disease Prevalence
- 7.3.3.3. Competitive Scenario
- 7.3.3.4. Regulatory Framework
- 7.3.3.5. Canada bioprocess automation market, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Target Disease Prevalence
- 7.3.4.3. Competitive Scenario
- 7.3.4.4. Regulatory Framework
- 7.3.4.5. Mexico bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4. Europe
- 7.4.1. Europe bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Competitive Scenario
- 7.4.2.4. Regulatory Framework
- 7.4.2.5. UK bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Competitive Scenario
- 7.4.3.4. Regulatory Framework
- 7.4.3.5. Germany bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Competitive Scenario
- 7.4.4.4. Regulatory Framework
- 7.4.4.5. France bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Target Disease Prevalence
- 7.4.5.3. Competitive Scenario
- 7.4.5.4. Regulatory Framework
- 7.4.5.5. Italy bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Target Disease Prevalence
- 7.4.6.3. Competitive Scenario
- 7.4.6.4. Regulatory Framework
- 7.4.6.5. Spain bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Target Disease Prevalence
- 7.4.7.3. Competitive Scenario
- 7.4.7.4. Regulatory Framework
- 7.4.7.5. Denmark bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Target Disease Prevalence
- 7.4.8.3. Competitive Scenario
- 7.4.8.4. Regulatory Framework
- 7.4.8.5. Sweden bioprocess automation market, 2021 - 2033 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Target Disease Prevalence
- 7.4.9.3. Competitive Scenario
- 7.4.9.4. Regulatory Framework
- 7.4.9.5. Norway bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Competitive Scenario
- 7.5.2.4. Regulatory Framework
- 7.5.2.5. Japan bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Competitive Scenario
- 7.5.3.4. Regulatory Framework
- 7.5.3.5. China bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Competitive Scenario
- 7.5.4.4. Regulatory Framework
- 7.5.4.5. India bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.5. Australia
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Competitive Scenario
- 7.5.5.4. Regulatory Framework
- 7.5.5.5. Australia bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Competitive Scenario
- 7.5.6.4. Regulatory Framework
- 7.5.6.5. Thailand bioprocess automation market, 2021 - 2033 (USD Million)
- 7.5.7. South Korea
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Competitive Scenario
- 7.5.7.4. Regulatory Framework
- 7.5.7.5. South Korea bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Competitive Scenario
- 7.6.2.4. Regulatory Framework
- 7.6.2.5. Brazil bioprocess automation market, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Competitive Scenario
- 7.6.3.4. Regulatory Framework
- 7.6.3.5. Argentina bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7. MEA
- 7.7.1. MEA bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Competitive Scenario
- 7.7.2.4. Regulatory Framework
- 7.7.2.5. South Africa bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Competitive Scenario
- 7.7.3.4. Regulatory Framework
- 7.7.3.5. Saudi Arabia bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Target Disease Prevalence
- 7.7.4.3. Competitive Scenario
- 7.7.4.4. Regulatory Framework
- 7.7.4.5. UAE bioprocess automation market, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Target Disease Prevalence
- 7.7.5.3. Competitive Scenario
- 7.7.5.4. Regulatory Framework
- 7.7.5.5. Kuwait bioprocess automation market, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2024
- 8.4. Company Profiles/Listing
- 8.4.1. Thermo Fisher Scientific Inc.
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Sartorius AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Parker Hannifin Corp
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Merck KGaA
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Eppendorf SE
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. SIA Bioreactors.net
- 8.4.6.1. Overview
- 8.4.6.2. Product Benchmarking
- 8.4.6.3. Strategic Initiatives
- 8.4.7. Senieer
- 8.4.7.1. Overview
- 8.4.7.2. Product Benchmarking
- 8.4.7.3. Strategic Initiatives
- 8.4.8. Getinge
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Repligen Corporation
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
